Semaglutide is a GLP-1 receptor agonist. Under the brand name Wegovy, it was FDA approved in June 2021 for chronic weight management in eligible adults, as an adjunct to a reduced-calorie diet and increased physical activity. The same molecule is sold as Ozempic for type 2 diabetes at different doses.
Tirzepatide is a dual agonist that activates both the GLP-1 receptor and the GIP receptor. Under the brand name Zepbound, it was FDA approved in November 2023 for chronic weight management in eligible adults, also as an adjunct to diet and exercise. The same molecule is sold as Mounjaro for type 2 diabetes.
Both are once-weekly injections, both are prescription only, and both require a physician consultation and a good-faith exam before they can be prescribed. Neither is a cosmetic quick fix. They are chronic disease medications intended for adults who meet specific medical criteria.
How do the two medications work differently?
GLP-1 and GIP are incretin hormones your gut releases after you eat. Semaglutide mimics GLP-1 alone. That single pathway slows stomach emptying, increases feelings of fullness, quiets food-related thoughts for many people, and helps regulate insulin and blood sugar.
Tirzepatide works on the GLP-1 pathway and adds GIP receptor activity on top of it. GIP appears to play a role in how the body handles fat and insulin, and the working theory is that hitting both receptors produces a stronger combined effect on appetite and metabolism than GLP-1 alone. Researchers are still working out exactly how much the GIP component contributes, and honest clinicians will tell you the full mechanism is not completely understood.
In practical terms, the day-to-day experience on the two medications is similar. Both reduce hunger, both slow digestion, and both are titrated upward gradually over months to a maintenance dose.
What did the clinical trials actually show?
In the STEP 1 trial, published in the New England Journal of Medicine in 2021, participants taking semaglutide 2.4 mg lost an average of 14.9 percent of their body weight over 68 weeks, compared with 2.4 percent on placebo. In the SURMOUNT-1 trial, participants taking tirzepatide lost up to an average of 22.5 percent at the highest 15 mg dose over 72 weeks.
Those two trials tested different drugs in different populations, so for years the comparison was indirect. Then came SURMOUNT-5, a head-to-head trial published in 2025 that randomized participants directly between the two. Tirzepatide produced greater average weight loss, roughly 20.2 percent versus 13.7 percent for semaglutide over 72 weeks.
Here is the honest caveat those headlines usually skip. Every one of those numbers is an average, and averages hide enormous individual variation. Some people respond strongly to semaglutide and modestly to tirzepatide. Some people tolerate one and not the other. A meaningful share of semaglutide participants in these trials lost 20 percent or more, and some tirzepatide participants lost far less than the average. No trial number is a promise about your body, and no reputable provider will present it as one.
- STEP 1: semaglutide 2.4 mg, average 14.9 percent loss over 68 weeks, versus 2.4 percent on placebo
- SURMOUNT-1: tirzepatide, average losses of 16.0, 21.4, and 22.5 percent at the 5, 10, and 15 mg doses over 72 weeks
- SURMOUNT-5 head to head: tirzepatide averaged about 20.2 percent versus about 13.7 percent for semaglutide over 72 weeks
- All figures are trial averages that vary widely from person to person, never a guarantee of individual results
What are the side effects of semaglutide and tirzepatide?
The side effect profiles are more alike than different. Gastrointestinal symptoms dominate for both medications, most commonly nausea, vomiting, diarrhea, constipation, and reflux. These are usually mild to moderate, cluster around dose increases, and fade as the body adjusts. This is exactly why both medications are titrated slowly, starting at a low dose and stepping up over several months rather than jumping straight to the maintenance dose.
Less common but more serious risks apply to both, including pancreatitis, gallbladder disease, and kidney injury related to severe dehydration from persistent vomiting or diarrhea. Both drugs also carry a boxed warning because they caused thyroid C-cell tumors in rodent studies. Whether that risk translates to humans is unknown, but out of caution both are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN2.
Interestingly, in the SURMOUNT-5 head-to-head trial, gastrointestinal side effects leading to discontinuation were slightly more common with semaglutide than tirzepatide, so the stronger drug is not automatically the harder one to tolerate. Individual tolerance is genuinely unpredictable, which is one more reason ongoing physician supervision matters. Severe abdominal pain, signs of an allergic reaction, or symptoms of severe dehydration deserve immediate attention, and in a medical emergency, call 911.
Who should not take these medications?
Some exclusions are absolute. Anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not take either medication, per the boxed warning on both labels. Pregnancy is another clear exclusion. These medications should be stopped before a planned pregnancy and are not used while pregnant or trying to conceive.
A history of pancreatitis calls for serious caution and a careful individualized discussion, since both drugs have been associated with pancreatitis. Severe gastrointestinal disease such as gastroparesis, a history of certain gallbladder problems, and a prior serious hypersensitivity reaction to the medication are also reasons a physician may say no or choose a different path.
This screening is the entire point of the good-faith exam. A physician reviews your medical history, current medications, labs where appropriate, and your goals before anything is prescribed. Any provider willing to skip that step and ship you a vial after a web form is not protecting you.
Why is physician supervision required for GLP-1 medications?
Both semaglutide and tirzepatide are prescription-only medications, and for good reason. A legitimate program starts with a consultation and a good-faith exam so a physician can confirm you actually meet the FDA criteria for treatment, screen for the contraindications above, and check for interactions with medications you already take, including insulin and other diabetes drugs.
Supervision does not end at the first prescription. Dose titration decisions, managing side effects, monitoring for warning signs, adjusting other medications as weight comes off, and planning for maintenance or discontinuation all require a clinician who knows your case. Weight loss that outpaces what is safe, nutritional gaps, and muscle loss are real concerns that a supervised program watches for and an anonymous online seller does not.
The difference between a medically supervised program and a discount vial from an unregulated website is not branding. It is whether anyone qualified is accountable for what happens in your body.
How do physicians actually choose between semaglutide and tirzepatide?
If tirzepatide produced greater average loss in head-to-head data, why does anyone still start semaglutide? Because averages are only one input. In real practice the decision weighs several factors at once, and the trial numbers are often not the deciding one.
Physician judgment comes first. Your medical history, your other conditions, and how aggressive an approach makes sense for your situation shape the recommendation. Semaglutide has a longer track record for weight management and additional evidence in areas like cardiovascular outcomes that may matter for specific patients. Tolerance matters too. Some patients simply do better on one molecule than the other, and there is no way to know in advance.
Then come the practical realities. Insurance coverage frequently dictates the choice, since many plans cover one medication and not the other, or neither. Pharmacy availability still fluctuates. Cost differences between the brands can be significant depending on coverage and manufacturer savings programs. A good physician lays all of this out honestly and builds the plan around what is medically sound and actually sustainable for you, including the option to switch later if the first choice is not working.
What does a physician-supervised GLP-1 program cost at WholeHealth Hydration?
We are not going to publish a teaser number here, because honest pricing for GLP-1 care depends on which medication you and the physician choose, your dose over time, your insurance situation, and how long you stay in the program. Anyone quoting you one flat number before knowing any of that is guessing. Program pricing is discussed openly at your consultation, with no surprises and no pressure.
WholeHealth Hydration is based in Chino Hills and offers physician-supervised GLP-1 weight management programs, with FDA-approved medications prescribed only after a consultation and good-faith exam. Alongside weight management, our mobile IV drips support hydration and wellness during your program, which many clients appreciate when appetite is low and fluid intake drops. A licensed Registered Nurse delivers every drip and screens each client first. IV drips run $299 to $849, with most drips between $329 and $429, and NAD+ drips at $799 to $849.
We serve Chino Hills and the surrounding radius, including Chino, Yorba Linda, Diamond Bar, Anaheim Hills, Eastvale, Rancho Cucamonga, Corona, and Brea, with our fastest same-day response inside that home radius. Coastal Orange County and desert visits need 24 to 48 hours notice and a travel fee may apply beyond 30 miles of Chino Hills, quoted at booking. To talk through whether semaglutide or tirzepatide fits your situation, call (213) 652-2912 or book a consultation through our Calendly.
One thing we keep transparent: our program itself is private pay wellness care, and we do not bill insurance for our services. Many clients use HSA or FSA funds depending on their plan. Where insurance can matter is the medication itself, which your pharmacy benefit may or may not cover, and we help you understand realistic out of pocket costs at your consultation.
Frequently asked questions
Which is stronger, semaglutide or tirzepatide?
On average, tirzepatide. In the SURMOUNT-5 head-to-head trial, tirzepatide produced roughly 20.2 percent average weight loss over 72 weeks versus about 13.7 percent for semaglutide. But stronger on average does not mean stronger for you, because individual response varies enormously and some people lose more on semaglutide than the tirzepatide average. Stronger also is not automatically better if your history, tolerance, or insurance points the other way, which is why the choice belongs in a physician consultation rather than a headline.
Can I switch from semaglutide to tirzepatide?
Yes, switching is common and medically reasonable when it is physician managed. There is no direct milligram-to-milligram conversion between the two molecules, so your physician selects an appropriate tirzepatide starting dose based on your current semaglutide dose and how you have tolerated it, rather than simply starting you back at the lowest dose in every case. People switch because of plateaued results, side effects, insurance changes, or availability. Never switch on your own or stack the two medications, since dosing errors are where people get hurt.
What happens when you stop taking semaglutide or tirzepatide?
For most people, appetite returns and significant weight regain follows. In the STEP 1 trial extension, participants who stopped semaglutide regained about two thirds of their lost weight within a year, and similar regain patterns appear in tirzepatide withdrawal data from SURMOUNT-4. This is not a personal failure, it reflects that obesity is a chronic condition and the medication was actively treating it. An honest program plans for this from day one, whether that means long-term maintenance dosing, a supervised taper, or a structured lifestyle transition.
Are compounded semaglutide and tirzepatide safe?
The safe path is FDA-approved brand product, prescribed after a good-faith exam and dispensed through a licensed pharmacy. Compounded copies were temporarily permitted only while the brands were on the FDA shortage list, and that window closed in 2025 after the FDA declared both shortages resolved and ended the compounding grace periods. The FDA logged hundreds of adverse event reports tied to compounded versions, many involving dosing errors from multidose vials, and unregulated online sellers add the risk of unknown purity and ingredients. If a website offers these medications cheap, with no exam and no named physician, that is the warning sign, not the deal.
Do you still have to diet and exercise on semaglutide or tirzepatide?
Yes. Both medications are FDA approved specifically as an adjunct to a reduced-calorie diet and increased physical activity, and every major trial result was achieved alongside lifestyle intervention, not instead of it. Practically, the medications make the work easier by quieting hunger, but protein intake and resistance exercise matter even more than usual because rapid weight loss can take muscle along with fat. A supervised program addresses nutrition and movement as part of the plan, not as an afterthought.
How long does it take to see results on semaglutide or tirzepatide?
Most people notice reduced appetite within the first few weeks, and meaningful weight change typically builds over months as the dose is titrated upward. The headline trial numbers, 14.9 percent average in STEP 1 and up to 22.5 percent average at the highest dose in SURMOUNT-1, were measured at 68 and 72 weeks respectively, which is well over a year of consistent treatment. Early months on lower doses usually produce slower loss, and that is by design, since gradual titration is what keeps side effects manageable. Judging the medication at week six is judging it before it has reached full strength.
Does insurance cover semaglutide or tirzepatide for weight loss?
Sometimes, and coverage is honestly one of the biggest factors in which medication you end up taking. Many commercial plans cover one of the two, some cover both with prior authorization, and some exclude weight management medications entirely, while Coverage is changing. Medicare historically excluded weight loss medications, but as of mid 2026 a limited federal program has begun covering these medications for some eligible Part D enrollees, with clinical criteria and details that vary by plan. Commercial coverage also varies widely. Verify your own situation with your plan and pharmacy, and remember that our program itself is private pay wellness care. Manufacturer savings programs can change the math for eligible patients. At your consultation we walk through what the medication typically costs out of pocket and how your pharmacy benefit may apply and the realistic monthly cost before you commit to anything.